GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Wai Yuen Tong Medicine Holdings Ltd (HKSE:00897) » Definitions » Beneish M-Score

Wai Yuen Tong Medicine Holdings (HKSE:00897) Beneish M-Score : -1.67 (As of Jun. 08, 2024)


View and export this data going back to 1997. Start your Free Trial

What is Wai Yuen Tong Medicine Holdings Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score -1.67 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Wai Yuen Tong Medicine Holdings's Beneish M-Score or its related term are showing as below:

HKSE:00897' s Beneish M-Score Range Over the Past 10 Years
Min: -2.98   Med: -2.43   Max: -1.65
Current: -1.67

During the past 13 years, the highest Beneish M-Score of Wai Yuen Tong Medicine Holdings was -1.65. The lowest was -2.98. And the median was -2.43.


Wai Yuen Tong Medicine Holdings Beneish M-Score Historical Data

The historical data trend for Wai Yuen Tong Medicine Holdings's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Wai Yuen Tong Medicine Holdings Beneish M-Score Chart

Wai Yuen Tong Medicine Holdings Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.98 -1.81 -2.54 -2.73 -1.67

Wai Yuen Tong Medicine Holdings Semi-Annual Data
Mar14 Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -2.73 - -1.67 -

Competitive Comparison of Wai Yuen Tong Medicine Holdings's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Wai Yuen Tong Medicine Holdings's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Wai Yuen Tong Medicine Holdings's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Wai Yuen Tong Medicine Holdings's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Wai Yuen Tong Medicine Holdings's Beneish M-Score falls into.



Wai Yuen Tong Medicine Holdings Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Wai Yuen Tong Medicine Holdings for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 2.2114+0.528 * 0.862+0.404 * 0.9671+0.892 * 0.9245+0.115 * 0.9625
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.1638+4.679 * -0.026566-0.327 * 0.997
=-1.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar23) TTM:Last Year (Mar22) TTM:
Total Receivables was HK$338 Mil.
Revenue was HK$1,286 Mil.
Gross Profit was HK$612 Mil.
Total Current Assets was HK$2,702 Mil.
Total Assets was HK$7,014 Mil.
Property, Plant and Equipment(Net PPE) was HK$961 Mil.
Depreciation, Depletion and Amortization(DDA) was HK$113 Mil.
Selling, General, & Admin. Expense(SGA) was HK$537 Mil.
Total Current Liabilities was HK$1,657 Mil.
Long-Term Debt & Capital Lease Obligation was HK$1,032 Mil.
Net Income was HK$-21 Mil.
Gross Profit was HK$0 Mil.
Cash Flow from Operations was HK$166 Mil.
Total Receivables was HK$165 Mil.
Revenue was HK$1,391 Mil.
Gross Profit was HK$570 Mil.
Total Current Assets was HK$2,889 Mil.
Total Assets was HK$7,598 Mil.
Property, Plant and Equipment(Net PPE) was HK$956 Mil.
Depreciation, Depletion and Amortization(DDA) was HK$108 Mil.
Selling, General, & Admin. Expense(SGA) was HK$499 Mil.
Total Current Liabilities was HK$1,881 Mil.
Long-Term Debt & Capital Lease Obligation was HK$1,041 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(338.003 / 1286.428) / (165.316 / 1391.411)
=0.262745 / 0.118812
=2.2114

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(570.39 / 1391.411) / (611.777 / 1286.428)
=0.409936 / 0.475563
=0.862

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (2702.37 + 961.159) / 7013.815) / (1 - (2888.706 + 956.4) / 7597.713)
=0.47767 / 0.493913
=0.9671

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1286.428 / 1391.411
=0.9245

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(107.797 / (107.797 + 956.4)) / (113.049 / (113.049 + 961.159))
=0.101294 / 0.105239
=0.9625

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(537.112 / 1286.428) / (499.195 / 1391.411)
=0.417522 / 0.358769
=1.1638

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((1032.461 + 1657.188) / 7013.815) / ((1040.9 + 1881.314) / 7597.713)
=0.383479 / 0.384618
=0.997

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-20.515 - 0 - 165.815) / 7013.815
=-0.026566

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Wai Yuen Tong Medicine Holdings has a M-score of -1.67 signals that the company is likely to be a manipulator.


Wai Yuen Tong Medicine Holdings Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Wai Yuen Tong Medicine Holdings's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Wai Yuen Tong Medicine Holdings (HKSE:00897) Business Description

Traded in Other Exchanges
N/A
Address
39 Wang Kwong Road, Suite 3101, 31st Floor, Skyline Tower, Kowloon Bay, Kowloon, Hong Kong, HKG
Wai Yuen Tong Medicine Holdings Ltd is an investment holding company. The company's operating segment includes production and sale of Chinese pharmaceutical and health food products; production and sale of Western pharmaceutical and health food products and property investment and management and sale of properties in the agricultural produce market. It generates maximum revenue from the production and sale of Chinese pharmaceutical and health food products which include manufacturing, processing, and sale of traditional Chinese medicine which includes Chinese medicinal products sold under the brand name Wai Yuen Tong. Geographically, it derives a majority of revenue from Mainland China.
Executives
Wang On Group Limited 2501 Other
Tang Ching Ho 2501 Other
Yau Yuk Yin 2202 Interest of your spouse

Wai Yuen Tong Medicine Holdings (HKSE:00897) Headlines

No Headlines